新西兰没有为Keytruda早期三联负乳癌提供资金,尽管已经证明有好处,但有可能出现更先进的、无法治愈的病例。 New Zealand lacks funding for Keytruda in early-stage triple negative breast cancer despite proven benefits, risking more advanced, incurable cases.

在世界三重负乳腺癌日,新西兰乳腺癌基金会敦促新西兰增加药品预算,以扩大获得Keyturda早期三重负乳腺癌治疗的机会,这种治疗比其他类型进展更快,占先进病例的比例过高。 On World Triple Negative Breast Cancer Day, Breast Cancer Foundation NZ is urging New Zealand to increase its medicines budget to expand access to Keytruda for early-stage triple negative breast cancer, which progresses faster than other types and accounts for a disproportionate share of advanced cases. 虽然自2024年10月以来,该药物一直用于治疗先进的疾病,但尽管有证据表明该药物可以防止其发展,但仍无法早期使用。 Though the drug is funded for advanced disease since October 2024, it remains unavailable for early use despite evidence it could prevent progression. 治疗在药剂师的投资名单上, 但面对激烈的竞争, 面对新西兰GDP0.4%低的药品支出(远低于经合组织平均水平), The treatment is on Pharmac’s investment list but faces stiff competition amid New Zealand’s low 0.4% GDP spending on medicines—well below the OECD average. 基金会警告说,如果没有早期投资,更多的病人将患上无法治愈的疾病,强调及时获得治疗可以挽救生命并降低长期保健系统的成本。 The foundation warns that without earlier investment, more patients will develop incurable disease, stressing that timely access saves lives and reduces long-term health system costs.